aav serotype coMparison in drG neurons
Introduction
Adeno-associated virus (AAV) is increasingly regarded as one of the most useful gene therapy vectors, due to its low immunogenicity and apparent absence of toxicity. AAV-based vectors have been used successfully to direct transgene expression in a variety of tissues including the nervous system (Kaplitt et al., 1994 , McCown et al., 1996 , Peel et al., 1997 , Klein et al., 1998 ; reviewed in Peel and Klein, 2000, Ruitenberg et al., 2002) and a number of early phase clinical trials for neurological or ophthalmic diseases have been conducted or are underway (Mandel and Burger, 2004 , Kaplitt et al., 2007 , Bainbridge et al., 2008 , Arvanitakis et al., 2009 . These early AAV vectors were based on AAV serotype 2, but subsequently vectors have also been generated based on novel serotypes of AAV derived from primate and human populations (Rutledge et al., 1998 , Xiao et al., 1999 , Chao et al., 2000 , Gao et al., 2002 , Rabinowitz et al., 2002 . Usually these utilize the AAV2 inverted terminal repeats (ITRs), but are packaged with the capsid proteins of the other serotypes. These vectors have different cellular tropism and transduction properties to AAV2, e.g. following injection into mouse or rat brains, AAV1 and AAV5 have consistently shown transduction of greater numbers of neurons, improved spread through the parenchyma, and transduction of areas that were not transduced by AAV2 (Wang et al., 2003 , Burger et al., 2004 , Paterna et al., 2004 .
For many studies of the peripheral nervous system, it is desirable to be able to direct transgene expression to the primary sensory neurons in the dorsal root ganglia (DRG). Over-expression or viral-vector mediated knockdown of genes of interest would allow a large range of investigations into gene function during, among other things, regeneration after peripheral nerve injury and neuropathic pain. The central branches of these neurons also project into the spinal cord and, in the case of large-diameter neurons, up to the brainstem, making them also a useful model in the study of regeneration in the central nervous system. HSVbased vectors and rabies-pseudotyped lentivirus have been used successfully (Lilley et al., 2001 , Glorioso et al., 2003 , Wong et al., 2006 but transduction with these vectors may sometimes be inefficient or transient. AAV vectors based on AAV2 were shown to be effective by direct injection of the ganglion (Glatzel et al., 2000 , Xu et al., 2003a and were used to deliver an antinociceptive gene (Xu et al., 2003b) . Storek et al. tested several serotypes for gene delivery following delivery in the intrathecal space, and found that self-complementary AAV8was the most effective in transducing DRG neurons (Storek et al., 2006 , Storek et al., 2008 , using it to deliver analgesic genes. AAV6 delivered intrathecally or via nerve injection was also recently shown to be effective at delivery of GFP to DRG neurons (Towne et al., 2009) .
Direct injection of DRG for gene delivery may be preferable for some experiments where transduction of specific ganglia is required, and might lead to higher transduction rates. However the transduction profiles of the different AAV serotypes using this delivery method are not known. We have compared AAV vectors based on serotypes 1, 2, 3, 4, 5, 6 and 8 for transduction of DRG neurons following injection of titre-matched viral vector stocks directly into the DRG. Viral vectors were prepared using serotype-specific packaging plasmids, but for all vectors we used an identical transfer plasmid consisting of a CMV-GFP-WPRE expression cassette flanked by AAV2 ITRs. It is also not known whether VSV-G pseudotyped lentiviral (LV) vectors are able to transduce DRG neurons in vivo. Since these vectors are widely used in the nervous system, the performance of the AAV serotype vectors was also compared with an LV vector. We have also examined the time-course of transgene expression of the three most successful vectors (AAV1, AAV5 and AAV6) up to three months after injection. To accurately compare the serotypes, we used a semi-automated method to quantify GFP expression in histological sections of DRG, allowing unbiased measurement of transgene expression in large numbers of sensory neurons. Additionally, to compare the vectors' efficacies at the level of transcription, we measured total GFP mRNA expression levels by qPCR.
Results

Comparison of AAV serotypes and lentivirus for gene delivery in dorsal root ganglia
Vectors based on AAV serotypes 1, 2, 3, 4, 5, 6 and 8, and lentivirus, were injected into the left L4 and L5 dorsal root ganglia of four animals per group. Two weeks after virus injection, all AAV serotypes except AAV3 had transduced significant numbers of DRG neurons (Fig 1) . Transduction appeared to be neuron specific from all AAV vectors except AAV6, as all transduced cells were TuJ1 positive and no other cells expressing GFP were observed. In the case of AAV6 we frequently observed satellite cells within the ganglion which had also been transduced. These cells were S100 positive (Fig. 2) . To confirm the neuronal specificity of transduction in the other AAV serotypes, sections from each serotype were also co-stained for GFP, TuJ1 and S100 and examined by confocal microscopy. Only neuronal transduction was seen and no satellite cells were transduced (Fig.  S1 ). LV-GFP transduced only a handful of neurons, although it did produce GFP expression in non-neuronal cells predominantly located in the intra-ganglionic nerve bundles (Fig. 1) .
GFP expression in the DRG neurons was quantified using a semi-automated histological method, using ImagePro Plus to identify neuronal nuclei visible after βIII tubulin staining. An example of automated identification of DRG nuclei is shown in Fig. 3a -c. The algorithm identified an average of 830 neurons from 11-12 sections per DRG, and in this study a total of 160,000 neurons were quantified. The percentage of neurons expressing GFP 2 weeks after injection are shown in Fig. 4a . AAV5 shows the highest average transduction rate of 48.7±4.1%, followed by AAV6 and AAV1 at 37.3±7.4% and 33.5±3.5% respectively. AAV5 was significantly higher than all other vectors except AAV1 and AAV6 (ANOVA followed by Dunnett's T3 post-hoc test; p<0.01). AAV8, AAV2 and AAV4 were the next best serotypes, in that order, while AAV3 performed poorly. The average expression levels of GFP in transduced cells per DRG were not significantly different between vectors (Fig.4b) .
Expression levels of GFP mRNA from all injected ganglia were also quantified by qPCR. eGFP values were normalized to neuron-specific enolase (NSE). As shown in Fig. 4c , the results were similar to those of the histological quantification method. Serotypes 1, 5 and 6 showed the highest expression. Total GFP mRNA expression from AAV1, 5 and 6 was very similar, while as before AAV3 and 4 were the poorest performing serotypes and AAV2 and AAV8 gave expression levels in between. AAV5 was significantly better than AAVs 1, 3, 4, 8 and LV (p<0.01) and AAV2 (p<0.05) (ANOVA with Dunnett's T3 post-hoc test).
Replicate viral batches
Although the viral stocks were carefully titre-matched and confirmed to be active using in vitro transduction assays, the possibility remained that some of the differences we observed between AAV serotypes may have been due to variation in production quality of viral batches. To rule out this possibility we performed a replicate set of injections for AAV serotypes AAV 1, 2, 5, 6 and 8 using independently made batches. These serotypes represent the best performing serotypes from the first comparison (AAV 1, 5 and 6), the classical and most widely used serotype AAV2, and AAV8 which was previously reported effective at transducing DRG neurons (Storek et al., 2008) .These data are shown in Fig. S2 . The findings are highly similar to the initial screen, AAV1, 5 and 6 being superior to AAV2 and 8. As before, AAV6, but not other serotypes, transduced satellite cells as well as neurons (data not shown). qPCR expression data from the replicate virus batches similarly confirmed the findings of the initial comparison. Relative expression levels are shown in Fig. S2c . Again, AAVs 1, 5 and 6 performed better than AAVs 2 and 8. 
Time-course of expression from AAV1, AAV5 and AAV6
We took the three serotypes which performed best at 2 weeks post-injection and examined the time-course of GFP expression. Left L4 and L5 DRGs were injected in 4 animals for each virus and each time-point. Survival times were 1 week, 4 weeks and 12 weeks after injection. Fig. 4d shows the transduction rates over the time course for these three serotypes. The percentage of GFP-positive cells 2, 3, 4, 5, 6 and 8 and a lentiviral (LV) 
vector, 2 weeks after injection. (a) Percentages of neurons expressing GFP. Points represent transduction rates from individual ganglia. (b) Average expression level per DRG, expressed as a multiple of background fluorescence. For each ganglion, the mean log expression level of GFP-expressing cells was calculated. (c) Relative mRNA expression levels determined by qPCR. Values are shown on a log-2 scale. (d, e, f) Time course of GFP expression after injection of AAV1, AAV5 and AAV6. The 2 week time-point is included again for clarity. (d) Percentages of neurons expressing GFP. Circles represent transduction rates from individual ganglia. (e) Average expression level per DRG, calculated as in b. (f) mRNA expression levels determined by qPCR, as in (c). *p<0.05, ** p<0.01, ***p<0.001 (ANOVA and Dunnett's T3 post-hoc test, a-c; 2-way ANOVA and Dunnett's post-hoc test, d-f). Error bars are S.E.M., n=8 DRG.
and the amount of GFP per cell expressed from AAV1 and AAV5 (Fig. 4e) clearly increased over the initial 4-week period and AAV5 showed a further increase in both measures at 12 weeks. This increase in expression was also clearly visible ( Fig. 5a , c, e). AAV5 was consistently the most effective serotype of these three. Over the time-course, the transduction rates delivered by AAV5 were significantly greater than those of both AAV1 and AAV6 (2-way ANOVA, Dunnett's post-hoc test; p<0.05). GFP-positive cell numbers from AAV6 expression peaked at 4 weeks at 75.5±6.6% but then declined markedly between 4 weeks and 12 weeks. At 12 weeks the transduction rate from AAV6 was significantly lower than that of AAV5 (Student's t-test; p<0.001).
eGFP mRNA expression was also quantified over the time-course by qPCR. Relative expression is shown in Fig. 4f . Expression was highest overall from AAV5. Expression from AAV1 slowly increased over the time course, reaching its maximum at 12 weeks. mRNA expression by AAV5, however, was already high at 1 week after injection and stayed at this level for the time-course. Expression from AAV6 increases from 1 to 4 weeks and then declines at 12 weeks, reflecting the histological expression data. The maximum RNA levels attained by each serotype were similar. AAV5 expression was significantly higher over the timecourse than AAV1 or AAV6 (2-way ANOVA, Dunnett's post-hoc test; p<0.01).
High-titre AAV5
Although the average AAV5 transduction rate at 12 weeks was as high as 77%, at 2 weeks only 49% of neurons were detectably GFP positive. We made a higher titre stock of AAV5 to determine if we could achieve a higher transduction rate at this time-point. We injected approximately a 10-fold higher number of viral genomes (5.5x10 9 ) into left L4 and L5 DRGs of four animals. The mean transduction rate 2 weeks after injection was significantly increased, at 61.9±4.4% as compared to 48.7±4.1% after injection of the lower titre stock (Student's t-test; p<0.05) (Fig.  S3a) .The expression level of the GFP positive cells was also significantly increased from 5.0±0.3 times background with the initial titre to 6.7±0.4 times background with the higher titre (Student's t-test; p<0.01; Fig. S3b ). qPCR quantification of eGFP expression revealed that mRNA expression was 5.6-fold higher from high titre virus injections than the standard titre (Student's t-test; p<0.001); shown on a log-2 scale in Fig. S3c .
Histology of injected ganglia
To determine if the injection procedure causes significant damage to the DRG we stained sections of injected ganglia with haemotoxylin and eosin. Two weeks after injection we could find little evidence for tissue damage (Fig. S4 ). Because we also observed an unexpected reduction in expression from AAV6 between 4 and 12 weeks we also carefully examined sections of 12-week injected DRG with H&E and double staining with S100 and GFP (Fig. S5) . We observed that in AAV6-injected DRG an area of apparent tissue damage had formed at 12 weeks (a, c, e), 50µm (b, d, f), 250µm (g). around the injection site, while with the other serotypes little or no evidence of damage was visible. GFP-positive neurons appeared to be often near the edge of the damaged area.
. Histology of time-course of GFP expression after injection AAV5. (a-f) Sections were stained with GFP (green) and βIII tubulin (red). (a, c, e) DRG neurons expressing GFP, 1 week (a), 4 weeks (c), and 12 weeks (e) after viral injection. (b, d, f) Sciatic nerves containing GFP-positive fibres, again 1 week (b), 4 weeks (d), and 12 weeks (f) after
GFP in sciatic nerve and spinal cord
Spinal cords and sciatic nerves of animals injected with AAV5 were processed for GFP immunohistochemistry. At 1 week, only occasional single GFP-positive axons could be seen in the sciatic nerve but at later time-points many fibres were labelled (Fig. 5b, d , f), with the most intense labelling seen at 12 weeks. Sections of lumbar spinal cord from 4 week AAV5-injected animals were also stained for GFP and again many GFP-positive axons were visible in the dorsal roots, and entering the cord (Fig. 5g) .
Transduction of neuronal sub-types
The primary sensory neurons of the DRG consist of several subtypes, which can be broadly classified as large-diameter, small-diameter peptidergic and small-diameter non-peptidergic. To determine if AAV1 and AAV5 transduce the different subtypes equally, we examined a subset of sections from 4 injected DRGs from the 4-week time-point. These were co-stained with CGRP, a marker for the small peptidergic neurons, or IB4, a marker for small non-peptidergic neurons, alongside GFP and βIII tubulin. CGRP-positive and IB4 positive neurons were also transduced by AAV1 and AAV5 (see Fig. 6a-f for examples) . A total of 33% of neurons were CGRP positive and 48% were IB4 positive. Transduction rates and mean expression levels of CGRP positive neurons were not significantly different to the overall population. However, the transduction rates of IB4 positive neurons were significantly lower than the overall transduction rates, for both serotypes (p<0.01; Student's t-test, paired). Mean expression levels per DRG were also lower in the case of IB4+ cells transduced by both serotypes, although this was only significant in the case of AAV5 (p<0.01; Student's t-test, paired). Figure 7 shows the transduction rates and mean expression levels for each serotype in CGRP+ and IB4+ cells, expressed as a percentage of the overall transduction rate in the sample sections.
AAV5 transduction of contralateral DRGs
Sections of contralateral uninjected DRGs were used to calibrate the background fluorescence level for subsequent quantification of GFP expression. However we noticed that following injection of AAV5 into the left L4 and L5 DRGs, a small number of neurons in the contralateral DRGs were transduced (not shown). The transduction rate was low, less than 1 neuron per section. Transduction of contralateral DRG neurons was not seen with any of the other serotypes. Because of this transduction at a distant site we also looked for GFP immunolabelling in meninges and sections of lumbar spinal cord, brain stem and forebrain of AAV5 injected animals. A very few transduced neurons were observed in the spinal cord, and no transduced cells were observed in the brainstem, forebrain or meninges. 
Discussion
We have compared viral vectors based on AAV serotypes 1, 2, 3, 4, 5, 6 and 8 and lentivirus for gene delivery to primary sensory neurons of the adult rat following direct injection of the DRG. We have accurately quantified both transduction rate and expression level from these vectors using automated image analysis, and mRNA expression by qPCR, and we show that AAV5 is the most effective in this model. The maximum transduction rate that we obtained, from AAV5, was 95%, which is remarkably high for in vivo viral vector delivery. AAV1 is also effective, but the transduction rate and protein expression level from this vector were consistently below AAV5. AAV6 also performs well at time-points up to 4 weeks after injection but its usefulness is limited by a severe decline in transgene expressing cells between 4 and 12 weeks. The onset of transcription from AAV5 also appears to be the most rapid, reaching its maximum already at 1 week, while mRNA levels from AAV1 and AAV6 increased more slowly. Protein levels, on the other hand, as measured by histological quantification, appear to increase more gradually, which may be because eGFP protein accumulates slowly. This effect was also seen by Xu et al. (Xu et al., 2003a) who found a large increase in the number of apparently transduced cells, between 1 and 3 weeks, following direct DRG injection of AAV2. The observations in DRG 12 weeks post-injection suggests that in the best injections nearly all neurons are transduced, but at earlier time points not enough GFP has been produced to be detectable. This may explain why injection of a near ten-fold higher titre of AAV5 resulted in only a modest increase in the average transduction rate at 2 weeks, compared to the standard titre we used for the serotype comparisons, although substantial increases in cellular expression level and mRNA were found. Collectively these observations indicate that with the current injection procedure, titres and the use of the AAV5 serotype we have achieved close to the maximum possible transduction rate of DRG neurons in vivo.
Several groups have reported transduction of DRG neurons with other AAV serotypes and delivery methods. Storek et al compared AAV serotypes 1, 3 and 5 by intrathecal delivery and although the DRG were not examined directly, only AAV1 produced strong GFP expression in cauda equine (Storek et al., 2006) . The same group compared AAV8 and AAV1 using this delivery route and found the former to be effective at transducing DRG neurons, and the better of the two serotypes (Storek et al., 2008) . While these findings differ from ours this is likely to be largely because of the very different delivery methods (intrathecal vs. direct injection). The AAV8 vector used by this group was also, unlike ours, self-complementary, which may explain why AAV8 was less effective in our hands than in their study. Foust et al. (Foust et al., 2008) reported sensory fibre labelling following intraperitoneal or intravenous injection of AAV8 in neonatal animals. AAV6 was also found to be effective for GFP delivery via intrathecal injection and sciatic nerve injection (Towne et al., 2009) . Several groups have used AAV2 to deliver gene expression to DRG neurons by direct injection and it has been used to deliver therapeutic genes (Glatzel et al., 2000 , Xu et al., 2003a , Xu et al., 2003b . However, as we now show, much more robust expression should be attainable with AAV5 compared to AAV2. Our findings are consistent with studies which have tested various AAV serotype vectors following injection in the adult rodent brain or spinal cord, where AAV1 and AAV5 have been shown to be effective delivery vectors (Wang et al., 2003 , Burger et al., 2004 , Paterna et al., 2004 , Klein et al., 2006 , Blits et al., 2010 . However, AAV8 was reported to outperform AAV1, 2 and 5 in hippocampus and substantia nigra (Klein et al., 2006) . Which vector performs best depends on the area being injected within the CNS and the cell-type being targeted; e.g. in the retina, AAV2 and 6 were the best and AAV5 and 8 were the least effective following intravitreal injection (Hellstrom et al., 2009 ). AAV4, which performed poorly in the DRG, was found to efficiently transduce ependymal cells (Davidson et al., 2000) . Lentivirus vectors, which did not transduce neurons efficiently in this study, do transduce neurons and astrocytes in the CNS, astrocytes in the neural scar (Naldini et al., 1996a , Blomer et al., 1997 , Ahmed et al., 2004 , Taylor et al., 2006 , Hendriks et al., 2007b and Schwann cells in peripheral nerve (Eggers et al., 2008) . In the DRG, the choice of AAV serotype for experimental study will depend on the experiment. Direct injection of AAV5 into DRG has the advantage of targeting specific ganglia and may also be desirable where maximal transduction rates, high expression levels and early onset of expression are required. However, the surgery is more invasive and time-consuming compared to intrathecal delivery of AAV8 or AAV6.
AAV6 appears to transduce neurons with a similar efficiency to AAV5 after direct injection, as indicated by counts of GFP positive cells that were comparable to those of AAV5 up to 4 weeks after injection. However, this vector shows a remarkable decline in expression between 4 and 12 weeks after injection with the average transduction rate falling back to a similar level to that seen at 1-2 weeks. This was associated with a notable area of damage around the injection site, visible at 12 weeks. This suggests that GFP expressing cells may be lost between 4 and 12 weeks post-injection due to tissue loss around the injection site. This effect may be caused by an immune response, either to AAV6 capsid or to GFP. AAV6 was the only serotype to also express GFP in satellite cells, and as we have previously found that GFP expression in Schwann cells provokes an immune response (which is ameliorated by the use of a non-immunogenic 'stealth GFP' (Hendriks et al., 2007a) ), it is possible that this loss of expression is a consequence of the transgene expression in the satellite cells leading to an immune reaction in a similar way. We speculate that this does not occur with the other serotypes because transduction is neuron specific and neurons are poor at antigen presentation. This point would be interesting to investigate further in future studies. Lastly, Towne et al. recently showed AAV6 to be effective at transducing DRG neurons after intrathecal delivery or sciatic nerve injection (Towne et al., 2009) and we note that these authors did not find transduction of satellite cells, so for this reason intrathecal delivery may be preferable to direct injection when AAV6 is used.
Unexpectedly, we saw GFP-expressing neurons distant from the injection site following delivery of AAV5, in contralateral DRG and occasionally in lumbar spinal cord. This may be due to travel of the virus within the blood stream or CSF, and it may also indicate retrograde transport of AAV5 by these neurons. In other studies neuronal retrograde take-up of AAV5 has been observed (Wang et al., 2003 , Burger et al., 2004 , Taymans et al., 2007 although, unlike AAV1, it was not effective at transduction of motor neurons by retrograde transport from the sciatic nerve (Hollis et al., 2008) . Care should be taken if GFP is to be considered for use as an axonal tracer, for example in spinal cord lesion models, as the transduction of neurons away from the injection site may lead to misleading results, if fibres from these neurons are also present at the site of interest.
In conclusion, we find that AAV5 is an excellent vector for gene delivery to dorsal root ganglion neurons, if direct injection is used. AAV1 is also effective but overall was out-performed by AAV5. Transduction of the great majority of neurons in the DRG is possible. The reliably high transduction rate will make this vector attractive for the over-expression of genes of interest in the DRG or, potentially, knockdown of specific genes by expression of hort hairin RNAs
Methods
Production of viral particles
AAV vectors encoding enhanced green fluorescent protein (GFP) were all generated using the plasmid pTRCGW (Ruitenberg et al., 2002 , Ahmed et al., 2004 . This contains the inverted terminal repeats of AAV2 flanking a CMV promoter driving expression of GFP, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) and a polyadenylation signal. Helper plasmids used for cross-packaging were generously provided by Dr Kleinschmidt (AAV1-6) and J. Wilson (AAV8) and used as described previously (Gao et al., 2002 , Grimm et al., 2003 . For each AAV serotype, 30 roller bottles of 293T cells were transfected with the respective plasmids using the calcium phosphate method. For AAV1-6, pTR-CGW was co-transfected with the serotype-specific helper plasmid (ratio 1:3; total DNA 200ug/bottle). For AAV8, pΔF6, p5E18 and pTRCGW were cotransfected (ratio 2:1:1, total DNA 200 ug/bottle). Cells were grown in 50 ml Iscoves Modified Eagle Medium (IMEM) without phenol red and pyruvate, with 10% fetal calf serum and penicillin/streptomycin (Invitrogen). Three days after transfection AAV was harvested in 5 ml lysis buffer (50 mM Tris pH 8.5, 2 mM MgCl, 150 mM NaCl, 0.1 % Triton X-100) per roller bottle, incubated for 1 h with 10 μg/ml DNAse, and spun down (30 min 4000G). The supernatant was filtered (0.45 μm), to yield crude lysate containing the AAV particles. AAV serotypes 1 and 5 were purified using affinity chromatography (Oranje et al., 2004) , serotypes 2, 3 and 4 were purified using iodixanol gradient centrifugation (Zolotukhin et al., 1999) , and serotypes 6 and 8 were purified using anion exchange chromatography (Zolotukhin et al., 2002) followed by iodixanol purification. For all vector stocks, the buffer was changed to DPBS / 5% sucrose using Amicon® Ultra-15 (Millipore) concentrators and the viral stock concentrated to the appropriate volume. High titre stock of AAV5 was made by subsequent further concentration of 1 ml of vector stock of titre 1x10 12 genomic copies(GC)/ml to approximately 150µl using a Centricon YM-100 (Millipore b.v., Amsterdam, the Netherlands). All vector stocks were kept at -80 o C until use. AAV stocks were assessed by SDS-PAGE analysis for visualization of the three capsid proteins (Grimm et al., 2003) . Infectivity was assayed by application of viral stocks to campthothecin-treated (4.8 μg/ml for 4 h) 293T cells, and inspection after 3 days under a fluorescence microscope. Titres were determined by quantitative PCR for viral genomic copies extracted from DNase-treated viral particles. Titres were in the range of 6.6x10 11 -1.5x10
12 GC/ml. Prior to injection, all vectors were titre-matched by dilution to 6.6x10
11 GC/ml with D-PBS/5% sucrose. Lentiviral vectors were produced as described previously (Naldini et al., 1996b , Ahmed et al., 2004 . The lentivirus expression cassette (pRRLsin-PPT-CMV-GFP), like the AAV cassette, contained the CMV promoter driving GFP expression, and a WPRE. Titre of the lentiviral vector encoding GFP was 1x10 9 transducing units (TU)/ml.
Experimental animals and surgical procedures
In this study a total of 72 female Wistar rats (200-250 g; Harlan, Horst, the Netherlands) were used. Animals were housed under standard conditions with food and water ad libitum, and a 12h:12h light/dark cycle. All experimental procedures and post-operative care were carried out with approval from the local animal experimentation ethical committee. The injection was performed with a borosilicate glass capillary (0.78mm/1mm internal/external diameters; Harvard Apparatus, Holliston, MA) pulled to a fine point, attached by Portex polythene tubing (0.4mm/0.8mm internal/external diameter; Jencon's Scientific Ltd, East Grinstead, UK) to a Hamilton syringe mounted in a Harvard PHD2000 microinjection pump (Harvard Apparatus, Holliston, MA). The needle was mounted on an extended arm of a stereotaxic frame swung to the outside (used to hold and manipulate the needle only). Tubing, syringe and needle were all filled with water. The viral vector solution was supplemented with 0.1 volumes of 1% Fast Green FCF (to allow monitoring of the injection of the viral vector solution into the ganglion). 1µl air was taken up in to the needle followed by 1.1µl of the viral vector solution. The needle was loaded separately with this volume for each injection. Animals were anaesthetized using Hypnorm (Fentanyl/ Fluanisone; 0.08 ml/100 g body weight, i.m.; Janssen Pharmaceuticals, Beerse, Belgium) and Dormicum (Midazolam; 0.05 ml/100 g body weight s.c.; Roche, Almere, the Netherlands). Following an incision along the dorsal midline, the L4 and L5 DRG were exposed by removal of the lateral processes of the vertebrae. The epineurium lying over the DRG was opened, and the glass needle inserted into the ganglion, to a depth of 400µm from the surface of the exposed ganglion. After a 3 minute delay to allow sealing of the tissue around the glass capillary tip, 1.1ul virus solution was injected at a rate of 0.2 µl/min. After a further delay of 2 minutes the needle was removed. The L4 ganglion was injected first followed by L5. The muscles overlying the spinal cord were loosely sutured together with a 5/O suture and the wound closed. Animals were allowed to recover at 37 °C and received post-operative analgesia (Temgesic 0.03 ml/100 g body weight s.c., Schering-Plough B.V., Maarssen, the Netherlands).
Comparison of AAV serotypes and lentivirus
Vectors based on AAV serotypes 1, 2, 3, 4, 5, 6 and 8 were injected into the left L4 and L5 dorsal root ganglia of four animals per vector. 6.6x10 8 genomic copies were delivered per injection. A further group of 4 animals received 1x10 6 transducing units (TU) per DRG of lentivirus expressing GFP, in the same volume. For AAV the ratio of GC to TU is in the range 500-1500 (Mayginnes et al., 2006) , so this titre of LV is comparable to the AAV and has been routinely used to transduced large numbers of cells in vivo (Hendriks et al., 2007b , Eggers et al., 2008 . After 2 weeks, animals were injected with a lethal dose of pentobarbital and transcardially perfused with 0.9% saline followed by 4% paraformaldehyde in 0.1M phosphate buffer pH 7.4. DRG were post-fixed for 3 to 4 hours and transferred to 30% sucrose in PBS, and the following day were frozen in TissueTek OCT (Sakura Finetek Holland BV, Zoeterwoude, Netherlands). The three most successful serotypes derived from the first experiment, AAV 1, 5 and 6 were studied in more detail. For each of these vectors, 12 further animals received injections in the left L4 and L5 DRG, with identical titre and injection volume, as before. After survival times of 1 week, 4 weeks and 12 weeks (n=4 per vector and time-point), animals were sacrificed and tissue processed as before. In one further group of 4 animals, 5.5x10 9 genomic copies of AAV5-CMV-GFP-WPRE were injected into the DRGs as above, again in 1.1µl total volume. A further 20 animals received injections of separately produced batches of serotypes 1, 2, 5, 6 and 8 (n=4 per serotype). The survival time for these groups was 2 weeks.
Immunohistochemistry
DRG were sectioned at 20µm thickness on a cryostat onto gelatinized slides. Every fourth section was stained with mouse anti-β III tubulin (clone TuJ1; Covance, Berkeley, CA) at 1:500, and rabbit anti-GFP (Abcam, Cambridge, UK) at 1:4000, followed by donkey anti-mouse Alexa594 (1:400) and biotinylated goat antirabbit (1:300; Vector, Burlingame, CA), and then streptavidin-Alexa488 (1:400). Co-localization of GFP and βIII-tubulin with CGRP, IB4 or S100 was performed on sections adjacent to those used for quantification: chicken anti-GFP (Millipore b.v., Amsterdam, the Netherlands) was used at 1:4000 followed by anti-chickenCy2 (1:400). Anti-tubulin TuJ1 and anti-mouse A594 were used as above. Anti-CGRP (Millipore; 1:1500) was followed by anti-rabbit Cy5 (1:400), and IB4-biotin (1:250; Vector, Burlingame, CA) was followed by streptavidin-Cy5 (1:400).
Anti-S100 (1:600, DakoCytomation B.V., Heverlee, Belgium) was followed by antrabbit A594. On spinal cord sections, rabbit anti-GFP was used as above with mouse anti-GFAP (Sigma, St Louis, MO; 1:400) followed by anti-mouse Alexa594. Fluorescent secondaries were from Invitrogen (Carlsbad, CA; Alexafluor labels) or Jackson ImmunoResearch (Newmarket, UK; Cy-dye labels).
Histological quantification
Every section was photographed at fixed exposure settings at 10x magnification on an Axioplan microscope (Zeiss, Sliedrecht, the Netherlands). GFP staining was imaged twice with different exposure times; a short exposure (25ms) for quantification and long exposure time (150ms) for visualization. The short exposure time used for quantification prevents saturation in the green fluorescence channel. Image analysis and quantification were performed in ImagePro Plus (MediaCybernetics, Bethesda, USA). When the DRG are stained for βIII tubulin, the nuclei are unstained and appear as a dark round object against the red signal of the cytoplasm. An algorithm was used to identify neuronal nuclei in the red channel based on roundness and size. GFP expression was quantified by measurement of green fluorescent intensity within the area of the nucleus. Uninjected contralateral DRG were also processed and quantified in the same way to provide a background measurement. For classification as a GFP-positive cell, a threshold of 2.25x the average background level was chosen. On sections co-stained with GFP and CGRP or IB4, thresholds were determined by visual inspection. Mean expression levels were calculated per injected ganglion as the mean log fluorescence level in GFP positive cells in the ganglion, and expressed as a multiple of background fluorescence.
qPCR
Gene expression was quantified using qPCR for eGFP mRNA. RNA extraction and qPCR on fixed material requires digestion of the tissue with proteinase K and the use of short (<80bp) amplicons (Lehmann and Kreipe, 2001, Specht et al., 2001) . Sections of DRG were removed from slides and RNA extracted as follows: sections were digested overnight in 100µl 25mM sodium citrate pH 7, 25mM EDTA 1% SDS, 4M urea and 12.5mg/ml proteinase K at 55 o C. 0.1 volumes sodium acetate pH4 was added and the RNA was phenol/chloroform extracted, precipitated and DNAseI treated (15 minutes at 25 o C). 750ng RNA of each sample was used as input for reverse transcription (RT) and a no RT control reaction. RT was performed using random hexamers and MMLV and the resulting cDNA treated with RNaseA. Primers for eGFP were: GTCTATATCATGGCCGACAA and CTTGAAGTTCACCTTGATGC. All expression values were normalized to that of neuron-specific enolase (NSE). NSE primers were: GGCAAGGATGCCACTAA and CGCTGTTCTCCAGGATATTG.
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